Delivery Order SPE2DB22D2214-SPE2DB25FS5TH
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $4,869.59 to AmerisourceBergen Drug Corp for 90 tablets of Myrbetriq ER 25 mg, a pharmaceutical product used in the treatment of overactive bladder. The contract was awarded on August 11, 2025, with an ultimate completion date of August 12, 2025, and represents a firm fixed price delivery order with no set-aside designation. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $3,490.90 to AmerisourceBergen Drug Corp for 90 tablets of Myrbetriq ER 25 mg, a pharmaceutical product used in the treatment of overactive bladder. This competitively awarded, firm fixed-price contract was executed on August 29, 2025, with an ultimate completion date of September 2, 2025. The order will be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. No set-aside designation was...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,109.65 to AmerisourceBergen Drug Corp for 90 tablets of Myrbetriq ER 50 mg, a medication used to treat overactive bladder. Awarded on August 11, 2025, with completion expected by August 12, 2025, this firm fixed-price delivery order carries no set-aside designation and represents a competitively awarded contract. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken,...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, received a competitive delivery order from the Defense Logistics Agency (DLA) valued at $2,471.47 for 90 tablets of Myrbetriq ER 25 mg, a pharmaceutical product used to treat overactive bladder. The award was made under a firm fixed-price delivery order contract type with an ultimate completion date of September 22, 2025. This delivery order is issued as a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $4,013.94 to AmerisourceBergen Drug Corp for 90-count tablets of Myrbetriq ER 50 mg, a medication used to treat overactive bladder. Awarded on July 22, 2025, with an ultimate completion date of July 23, 2025, this firm fixed-price contract utilized competitive procedures with no set-aside designation. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters and primary...
- The Defense Logistics Agency awarded a $6,839.18 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 90 tablets of Myrbetriq ER 25 mg, a branded pharmaceutical used to treat overactive bladder. The award, issued on May 30, 2025, with an ultimate completion date of June 2, 2025, represents a non-set-aside competitive award to the prime contractor. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal...
- The Defense Logistics Agency awarded a delivery order valued at $6,265.49 to AmerisourceBergen Drug Corp for 90-count tablets of Myrbetriq ER 50 mg, a medication used to treat overactive bladder. This non-competitive, firm fixed-price delivery order was issued on September 19, 2025, with an ultimate completion date of September 22, 2025. The order will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $6,868.68 for 90 tablets of Myrbetriq ER 25 mg on July 14, 2025, with ultimate completion by July 15, 2025. This non-set-aside contract employs firm fixed pricing and represents a delivery order under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The product will be performed at the contractor's Conshohocken, Pennsylvania location, the company's...
- The Defense Logistics Agency awarded a $33,234.95 delivery order to AmerisourceBergen Drug Corp for 90-count bottles of Myrbetriq ER 25 mg tablets, with a firm fixed price and an ultimate completion date of September 11, 2025. This non-set-aside competitive award represents a single delivery order issued under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $25,697.77 to AmerisourceBergen Drug Corp for the supply of Myrbetriq ER 50 mg tablets (90-count units) under a firm fixed-price contract. The award was made on August 29, 2025, with an ultimate completion date of September 2, 2025, and represents a non-set-aside competitive award. Performance will take place at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- SPE2DB22D2214Indefinite Delivery Contract
- SPE2DB22D2214-SPE2DB25FS5THDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,996.61 to AmerisourceBergen Drug Corp for 90 tablets of Myrbetriq ER 25 mg, a pharmaceutical product used to treat overactive bladder. The award was competitively procured with no set-aside designation and carries a firm fixed price structure. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the delivery from its corporate office location. The contract is scheduled for ultimate completion by July 15, 2025, with an award date of July 14, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. As a major pharmaceutical distributor, AmerisourceBergen supplies a comprehensive range of brand-name and generic medications, vaccines, and medical supplies to support military and federal healthcare systems. The parent IDC functions as a global pharmaceutical support vehicle enabling the company to fulfill medical supply needs across multiple therapeutic domains for customers including the Defense Health Agency and other government healthcare organizations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.0k | 7/14/25 |